Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.64 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.58 |
| ▸ | CCNK | O75909 | 2/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | CCND3 | P30281 | 2/20 | 0.57 |
| ▸ | CDK9 | P50750 | 2/20 | 0.57 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 10/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226380 | 0.89 | STK17A (0.58) | MAP4K1STK17ACCNA2CDK2CCND3 | |
| SCHEMBL229526 | 0.88 | ALK (0.59) | CCND3ALKCDK4CCND1EGFR | |
| SCHEMBL5494435 | 0.84 | MAP4K1 (0.57) | MAP4K1STK17AALKBRD4CDK4 | |
| SCHEMBL230101 | 0.84 | BRAF (0.50) | MAP4K1ALKSRC | |
| SCHEMBL5494517 | 0.81 | MAP4K1 (0.62) | MAP4K1STK17ACCNA2CDK2CCND3 | |
| SCHEMBL2573809 | 0.80 | YES1 (0.53) | FGFR1SRCFGFR4 | |
| SCHEMBL2573807 | 0.80 | SRC (0.53) | FGFR1SRCFGFR4WEE1 | |
| SCHEMBL27174693 | 0.80 | MAP4K1 (0.73) | MAP4K1CCNKCCNA2CDK2CCND3 | |
| SCHEMBL5497607 | 0.80 | LCK (0.61) | MAP4K1STK17ABRD4JAK2JAK3 | |
| SCHEMBL4892563 | 0.79 | CCND3 (0.56) | MAP4K1STK17ACCNKCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | MAP4K1 33/4885STK17A 830/4885CCNK 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.